Table 4.
Summary of included studies
| Study | Type of work | Location | Sample Size / Cohort | IG type | Study period | Study Design/Analysis |
|---|---|---|---|---|---|---|
| Alcantara et al. (2021) [32] | Journal article | Single site in Toronto, Ontario | 34 patients with generalized MG | IVIG & SCIG | 2015–2020 | Retrospective cohort study |
| Arnold et al. (2020) [50] | Journal article | Canada-wide | 74 patients with ITP | IVIG vs eltrombopag | 2013–2019 | Clinical trial (randomized, open-label)(Bridging ITP Trial) |
| Bourque et al. (2016) [31] | Journal article | Single site in Ottawa, Ontario | 9 patients with MG | IVIG & SCIG | 2015–2016 | Retrospective cohort study |
| Brownlee et al. (2022) [48] | Journal article | Single site in Ottawa, Montreal | 10 patients with PID or SID who did not tolerate the side effects of 20% SCIG | SCIG | 2018–2020 | Prospective cohort |
| Fu et al. (2018) [35]a | Journal article | Single site in Toronto, Ontario | 57 PID patients | SCIG & IVIG | Study published in 2018- | Cost savings study |
| Gerth et al. (2014) [34]a | Journal article | N/A | PID/SID patients | IVIG & SCIG | N/A | Cost savings simulation study |
| Hsia et al. (2015) [27] | Journal article | Two hospitals in Ontario | 383 adult patients with ITP | IVIG | 2003–2012 | Retrospective audit |
| Jutras et al. (2021) [26] | Journal article | Single site in Montréal Québec | 172 critically ill pediatric patients | IVIG | 2013–2018 | Retrospective cohort study |
| Kaur et al. (2022) [51] | Journal article | Canada-wide | 74 patients with ITP | IVIG vs eltrombopag | 2013–2019 | Cost-effectiveness analysis of data from Bridging ITP Trial |
| Keith et al. (2022) [46]a | Journal article | 6 centers across Canada (except Québec) | 125 Patients with PID or SID | SCIG | 2018–2020 | Phase 4, non-interventional, prospective, single-arm study |
| Kobayashi et al. (2022) [47]a | Journal article | Multi-national, including Canada | 102 patients with PID | SCIG | 238 weeks follow-up duration. Dates were not mentioned | Secondary analysis of data from previous single-arm phase 3 trials |
| Liu et al. (2019) [28] | Journal article | Single site in Toronto, Ontario | 40 patients with ITP | IVIG | 2014 | Audit |
| Mallick et al. (2022) [41]a | Journal article | Canada-wide | 296 Patients with PID or SID | SCIG & IVIG | 2020–2021 | Survey Study |
| Murphy et al. (2019) [17] | Journal article | Four sites in Ottawa, Ontario | 2629 patients | IVIG | 2007–2016 | Trend Analysis |
| Reid et al. (2014) [37] | Journal article | Referral centers or community hospitals in Ontario | 169 patients who were on hospital-based IG replacement therapy | IVIG & SCIG | – | Survey using questionnaire |
| Ritchie et al. (2022) [36]a | Journal article | Alberta, Province-wide | 7890 adult and pediatric patients who used IG products | SCIG & IVIG | 2012–2019 | Retrospective population-based cohort |
| Shih et al. (2017) [9] | Journal article | Four sites in Ontario | 178 adult patients | IVIG | 2014 | Audit |
| Sholapur et al. (2016) [38] | Journal article | Single site in Ontario | 12 ITP patients | IVIG | Study published in 2016- | Cross-sectional study |
| Suleman et al. (2019) [33]a | Journal article | Single site in Ottawa, Ontario | 19 patients with immune-mediated neurological disorders | IVIG & SCIG | 2010–2016 | Retrospective cohort study |
| Sultan et al. (2017) [39]a | Journal article | Single site in Montreal, Québec | 60 children with PID | SCIG | Study published in 2017- | Cross-sectional study |
| Tran et al. (2023) [29] | Journal article | Three hospitals in British Columbia | 114 patients with SID | SCIG & IVIG | 2018–2019 | Retrospective cohort/audit |
| Walter et al (2014) [45] | Journal article | Manitoba, province-wide | 62 patients with PID | SCIG | 2007–2018 | Retrospective |
| Abadeh et al. (2023) [49] | Conference abstract | Ontario, multicentre | 108 patients with SID | IVIG/SCIG | 2020–2022 | Cross-sectional |
| Furlan et al. (2016) [52] | Conference abstract | Ontario | 32 patients who received IVIG and 38 patients treated with plasma exchange | IVIG | 2007–2010 | Cost-minimization analysis |
| Mallon et al. (2016) [43] | Conference abstract | Alberta, multicentre | 8 patients with MG | SCIG | – | Clinical trial |
| Shabani-Rad et al. (2018) [30] | Conference abstract | Calgary, Alberta | IVIG recipients | IVIG | 2017 | Cross-sectional |
| Siddiqi et al. (2018) [44] | Conference abstract | Alberta, multicentre | 822 patients with MG | SCIG | – | Clinical trial |
| Streu et al (2016) [42] | Conference abstract | Manitoba, single centre | 53 patients with CLL | SCIG | Two year period | Prospective |
| Zhou et al. (2021) [40] | Conference abstract | Ontario, single centre | Adult patients receiving IVIG for Inflammatory Myositis | IVIG/SCIG | – | Survey |
IVIG: intravenous immunoglobulin; SCIG: subcutaneous immunoglobulin; MG: myasthenia gravis; ITP: immune thrombocytopenia; PID: primary immune deficiency; SID: secondary immune deficiency. The key findings of the publications in this table can be found in Additional file 1: Table S3
aStudies were funded by IVIG/SCIG manufacturers. Fu et al., Gerth et al., Mallick et al., Ritchie et al., Suleman et al., and Sultan et al. were funded by CSL Behring. Keith et al. were funded by Baxalta US Inc. and Baxalta Innovations GmBH. Kobayashi et al. was funded by Octapharma AG